Alvotech initiates confirmatory patient study for avt16, a proposed biosimilar to entyvio®

Alvotech (nasdaq: alvo), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for avt16, a biosimilar candidate to entyvio® (vedolizumab). the objective of the study is to demonstrate comparative efficacy, safety, and immunogenicity of avt16 and entyvio, in male and female participants 18-80 years old with moderate to severe active ulcerative colitis. alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to entyvio.
ALVO Ratings Summary
ALVO Quant Ranking